Article
CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
JCI insight - 23 Jan 2026
Hirsch Rebecca M, Droby Gaith, Premsankar Sunthoshini, Parrish Molly L, Kurnit Katherine C, Chiou Lilly F, Rabjohns Emily M, Lee Hannah N, Broaddus Russell R, Vaziri Cyrus, Bowser Jessica L
Abstract excerpt
Approximately 30% of patients with endometrial carcinomas (ECs) with exon 3 CTNNB1 (β-catenin) mutations experience disease recurrence, whereas others with the same mutations remain recurrence-free. The molecular factors driving mutant β-catenin's oncogenic and clinical variability are unknown. Here we show that CD73 restrains the oncogenic activity of exon 3 β-catenin mutants, and CD73 loss is associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.